EGFR and pancreatic ductal adenocarcinoma: Interestingly, erlotinib in combination with the chemotherapeutic agent gemcitabine showed efficacy in a patient with a pancreatic ductal adenocarcinoma carrying the EGFR:c.2189T>G p.(L730R) GV [54] that was also detected in a glioblastoma patient here.